Hematologic Malignancies: Clinical Trials

36 trials for Hematologic Malignancies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed. 36 Phase 2, 15 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 236Completed 36
Phase 115Completed 15
Phase 31Completed 1

Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)82023-04-052026-02-23
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Teclistamab - Hematologic Malignancies
Phase 1 / Phase 2CompletedJanssen Pharmaceutical K.K.402021-02-222026-06-05
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Tildrakizumab - Hematologic Malignancies
Phase 2CompletedMedical College of Wisconsin512020-03-012025-10-21
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Haplo HCT <55 years old, Haplo HCT ≥55 years old, GVHD Prophylaxis - Hematologic Malignancies
Phase 2CompletedMasonic Cancer Center, University of Minnesota782017-01-242025-05-28
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
ProTmune, Control Arm - Hematologic Malignancies, Acute Myeloid Leukemia
Phase 1 / Phase 2CompletedFate Therapeutics962016-12-202023-02-08
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
CC-486 - Hematologic Neoplasm, Neoplasms
Phase 2CompletedCelgene52015-10-222026-04-02
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Carfilzomib, Tacrolimus - Hematologic Malignancies, Relapse
Phase 1 / Phase 2CompletedUniversity of Michigan Rogel Cancer Center532014-10-012022-01-03
Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy
Cyclophosphamide - Hematologic Malignancies
Phase 2CompletedDartmouth-Hitchcock Medical Center582013-12-012021-02-16
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan - Hematologic Malignancies
Phase 2CompletedWeill Medical College of Cornell University2702012-10-162026-08-19
Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation
Bz (Bortezomib), Len (lenalidomide) - Hematologic Malignancies, Multiple Myeloma
Phase 1 / Phase 2CompletedEuropean Myeloma Network B.V.492011-11-012017-07-06
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Preparative Regimen - Hematologic Malignancies, Disorder Related to Transplantation
Phase 2CompletedSt. Jude Children's Research Hospital142011-06-152017-06-05
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Fludarabine, Cytoxan, Total Body Irradiation - Hematologic Malignancies
Phase 1 / Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins872010-09-012026-02-19
Umbilical Cord Transplantation for the Elderly Population
StemEx - Hematologic Malignancies
Phase 2CompletedLoyola University182010-01-012019-08-21
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Cyclophosphamide, Fludarabine, Melphalan - Blood Stem Cell Transplant Failure, Leukemia
Phase 2CompletedM.D. Anderson Cancer Center1762009-11-052020-03-25
Cytokine Induced Killer (CIK) Cells In Leukemia Patients
in vitro expanded Cytokine Induced Killer (CIK) cells - Hematologic Malignancies
Phase 2CompletedA.O. Ospedale Papa Giovanni XXIII742009-07-012019-01-23
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
GSK21110183 - Hematologic Malignancies
Phase 1 / Phase 2CompletedAccenture732009-07-012012-04-04
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis) - Hematologic Malignancies, Graft vs Host Disease
Phase 1 / Phase 2CompletedPavan Reddy, MD612009-01-012014-04-11
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia
Phase 2 / Phase 3CompletedGamida Cell -Teva Joint Venture Ltd.1012007-10-012015-07-10
Adult Double Cord Blood Transplant Study
Cord blood transplantation - Cord Blood Stem Cell Transplantation, Hematologic Malignancies
Phase 2CompletedCenter for International Blood and Marrow Transplant Research562007-08-012014-03-10
Phase II Trial of Pentostatin and Targeted Busulfan
Pentostatin, Busulfan, Rituximab - Hematologic Malignancies
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute422007-07-012014-06-05

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Hematologic Neoplasms (36)  ·  Graft vs Host Disease (9)  ·  Leukemia (8)  ·  Myelodysplastic Syndromes (8)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (7)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6)  ·  Leukemia, Myeloid, Acute (6)  ·  Lymphoma (6)  ·  Lymphoma, Non-Hodgkin (6)  ·  Hodgkin Disease (5)  ·  Multiple Myeloma (5)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Hematologic Diseases (3)  ·  Myeloproliferative Disorders (3)  ·  Neoplasms, Plasma Cell (3)

Broader conditions

Hemic and Lymphatic Diseases (36)  ·  Neoplasms by Site (36)  ·  Neoplasms (34)  ·  Hematologic Diseases (33)  ·  Immune System Diseases (20)  ·  Neoplasms by Histologic Type (17)  ·  Immunoproliferative Disorders (14)  ·  Lymphoproliferative Disorders (14)  ·  Lymphatic Diseases (13)  ·  Bone Marrow Diseases (11)  ·  Disease Attributes (9)  ·  Pathologic Processes (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Chronic Disease (6)  ·  Leukemia, Lymphoid (6)

Interventions

Tacrolimus (10)  ·  fludarabine (7)  ·  Cyclophosphamide (6)  ·  Mycophenolic Acid (5)  ·  Sirolimus (4)  ·  Whole-Body Irradiation (4)  ·  fludarabine phosphate (4)  ·  Busulfan (3)  ·  Melphalan (3)  ·  Methotrexate (3)  ·  Rituximab (3)  ·  Stem Cell Transplantation (3)  ·  Bortezomib (2)  ·  Mesna (2)  ·  Pentostatin (2)

Sponsors

Dana-Farber Cancer Institute (3)  ·  M.D. Anderson Cancer Center (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2)  ·  A.O. Ospedale Papa Giovanni XXIII (1)  ·  Accenture (1)  ·  Celgene (1)  ·  Center for International Blood and Marrow Transplant Research (1)  ·  Clavis Pharma (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  Emory University (1)  ·  European Myeloma Network B.V. (1)  ·  Fate Therapeutics (1)  ·  Gamida Cell -Teva Joint Venture Ltd. (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Janssen Pharmaceutical K.K. (1)

Countries

United States (28)  ·  Italy (4)  ·  Germany (3)  ·  Canada (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Japan (1)  ·  Norway (1)  ·  South Korea (1)  ·  Sweden (1)

Top investigators

Patrick Stiff, MD (2)  ·  Agha Mounzer, MD (1)  ·  Alberto Bosi, MD (1)  ·  Alessandro AR Rambaldi, Professor (1)  ·  Alexandra Gomez Arteaga, MD (1)  ·  Amelia Langston, MD (1)  ·  Amr Qudeimat, MD (1)  ·  Attaphol Pawarode, M.D. (1)  ·  Celia Grosskreutz, MD (1)  ·  Christelle Ferra, MD (1)  ·  Christopher J Melani, M.D. (1)  ·  Corey Cutler, MD, MPH (1)  ·  Cristina Arbona, MD (1)  ·  Denis-Claude Roy, MD (1)

Results publications

PMID 16115130, PMID 16980990, PMID 17162214, PMID 17606446, PMID 18451242, PMID 19462317, PMID 19713456, PMID 20685246, PMID 21868572, PMID 22491731, PMID 23065508, PMID 23524640, PMID 24295572, PMID 25075128, PMID 26869630, PMID 29242852, PMID 29477778, PMID 31135970, PMID 31217161, PMID 34425261, PMID 37882668, PMID 41485109, PMID 41632629

NIH funding

2023 (1), P01CA015396 (1)